4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic-acid and Hypertension

A multitarget pharmacologic approach could be advantageous for the therapy of metabolic multiple diseases, such as the metabolic syndrome, which is characterized by metabolic abnormalities associated with diabetes, obesity, hypertension, and increased cardiovascular risk. PPAR receptors play a critical role in metabolic disorders, affecting glucose and lipid metabolism. Drugs simultaneously targeting PPAR and other validated metabolic targets, represent a promising multitarget approach to combine antihyperglycemic, antihyperlipidemic, and antihypertensive effects. This review offers a survey of recently developed multitarget PPARγ agonists as antidiabetic and antihypertensive drugs.

Topics: Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypertension; Hypoglycemic Agents; Metabolic Syndrome; Molecular Structure; PPAR gamma; Structure-Activity Relationship